Himbergen T M, van Tits L J H, Voorbij H A M, de Graaf J, Stalenhoef A F H, Roest M
Research Laboratory of the Department of Clinical Chemistry, University Medical Centre Utrecht, Utrecht, the Netherlands.
J Intern Med. 2005 Nov;258(5):442-9. doi: 10.1111/j.1365-2796.2005.01557.x.
Statins reduce low-density lipoprotein cholesterol (LDL-C) and can raise high-density lipoprotein cholesterol (HDL-C). HDL-bound paraoxonase-1 (PON1) is associated with variations in plasma HDL-C, and may, therefore, contribute to changes of HDL-C during statin therapy.
The effects of baseline PON1 status to HDL-C changes because of statin therapy were investigated. PON1 status was determined with (i) PON1 -107C>T and 192Q>R genotype, (ii) PON1 levels and (iii) PON1 paraoxonase, diazoxonase and arylesterase activity.
Radboud University Nijmegen Medical Centre, Nijmegen, the Netherlands.
A total of 134 familial hypercholesterolaemia (FH) patients undergoing atorvastatin or simvastatin therapy.
PON1 levels and activities significantly modified the HDL-C increment (P=0.002 for PON1 levels and arylesterase activity and P=0.001 for diazoxonase activity). The effects were even more evident amongst subgroup classifications based on PON1 status and baseline HDL-C concentrations: the HDL-C increment was more pronounced in subgroups of -107CT/TT or 192QR/RR genotype combined with low baseline HDL-C (+13.9%, P<0.001, respectively+15.4%, P<0.001). In contrast, the -107CC or 192QQ genotype in combination with high baseline HDL-C, did not show a significant increase of HDL-C.
PON1 status in conjunction with baseline HDL-C levels predicts HDL-C increment during statin therapy in FH patients.
他汀类药物可降低低密度脂蛋白胆固醇（LDL-C），并能升高高密度脂蛋白胆固醇（HDL-C）。与高密度脂蛋白结合的对氧磷酶-1（PON1）与血浆HDL-C的变化有关，因此可能在他汀类药物治疗期间导致HDL-C的改变。
研究了基线PON1状态对他汀类药物治疗引起的HDL-C变化的影响。通过（i）PON1 -107C>T和192Q>R基因型、（ii）PON1水平以及（iii）PON1对氧磷酶、对二氧磷酶和芳基酯酶活性来确定PON1状态。
荷兰奈梅亨拉德堡德大学医学中心。
总共134例接受阿托伐他汀或辛伐他汀治疗的家族性高胆固醇血症（FH）患者。
PON1水平和活性显著改变了HDL-C的升高幅度（PON1水平和芳基酯酶活性的P值为0.002，对二氧磷酶活性的P值为0.001）。在基于PON1状态和基线HDL-C浓度的亚组分类中，这种影响更为明显：在-107CT/TT或192QR/RR基因型与低基线HDL-C的亚组中，HDL-C的升高更为显著（分别为+13.9%，P<0.001；+15.4%，P<0.001）。相比之下，-107CC或192QQ基因型与高基线HDL-C相结合时，HDL-C并未显著升高。
PON1状态与基线HDL-C水平共同预测FH患者他汀类药物治疗期间HDL-C的升高。
